Recombinant Bordetella pertussis pertactin (P69) from the yeast Pichia pastoris: high-level production and immunological properties

Michael A. Romanos, Jeffrey J. Clare, Katrina M. Beesley, Fred B. Rayment, Stuart P. Ballantine, Andrew J. Makoff, Gordon Dougan, Neil F. Fairweather, Ian G. Charles

Research output: Contribution to journalArticleResearchpeer-review

86 Citations (Scopus)

Abstract

Acellular whooping cough vaccines are based on pertussis toxoid but their effectiveness may be increased by the addition of other Bordetella pertussis antigens. We expressed the immunogenic outer membrane protein pertactin (P69) from B. pertussis to high levels in multi-copy transformants of the industrial yeast Pichia pastoris. In high-density fermentations, engineered P. pastoris yielded > 3 g of the protein per litre of culture. Purified recombinant pertactin was able to stimulate the incomplete protection afforded by toxoid to the level of the whole-cell vaccine, as shown by the Kendrick test, supporting its inclusion in future acellular vaccines.

Original languageEnglish
Pages (from-to)901-906
Number of pages6
JournalVaccine
Volume9
Issue number12
DOIs
Publication statusPublished - 1 Jan 1991
Externally publishedYes

Keywords

  • heterologous expression
  • P69
  • pertactin
  • Pertussis vaccines
  • Pichia
  • yeast

Cite this